O-behenoylcarnitine | 98865-31-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: O-behenoylcarnitine
• 英文别名: 3-docosanoyloxy-4-(trimethylazaniumyl)butanoate
• CAS: 98865-31-7
• 化学式: C29H57NO4
• 分子量: 483.8
• InChiKey: IUMXSSOVGPXXJL-UHFFFAOYSA-N

物化性质

• 碰撞截面：
  236.02 Ų [M]+ [CCS Type: TIMS, Method: single field calibrated]

计算性质

• 辛醇/水分配系数(LogP)：
  11
• 重原子数：
  34
• 可旋转键数：
  25
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Predicting coronary artery disease and risk of cardiovascular events
  申请人：Duke University

  公开号：US10317414B2

  公开（公告）日：2019-06-11

  Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease.

  本文公开了通过检测受试者样本中至少一种代谢物的水平来评估受试者心血管疾病风险的方法。代谢物的水平表明受试者罹患心血管疾病的风险。代谢物可以是酰基肉碱、氨基酸、酮、游离脂肪酸或羟丁酸。心血管疾病可以是心血管事件的风险、冠状动脉疾病的存在或发展为冠状动脉疾病的风险。
• Compositions and methods for metabolic profiling in subjects with heart failure with preserved ejection fraction
  申请人：Duke University

  公开号：US10451641B2

  公开（公告）日：2019-10-22

  Disclosed herein are compositions and methods for targeted metabolomics profiling to provide absolute quantification of a broad array of metabolic intermediates of fatty acids, amino acids, and carbohydrate metabolism for HFpEF. In an aspect, the disclosure relates to a method for assessing risk of death or a major adverse cardiac event (MACE) in a subject diagnosed with heart failure with preserved ejection fraction (HFpEF). The method may include (a) determining in a sample from the subject the level of each metabolite in at least one factor, wherein the factor is selected from the group consisting of factor 1, factor 3, factor 4, factor 5, factor 10, factor 12, and factor 14; and (b) comparing the level of each metabolite in the sample to a standard, wherein the level of the metabolite in the subject relative to a standard is indicative of the risk of death or MACE in the subject.

  本文公开了用于靶向代谢组学分析的组合物和方法，以提供针对 HFpEF 的脂肪酸、氨基酸和碳水化合物代谢的一系列代谢中间产物的绝对定量。在一个方面，本公开涉及一种用于评估被诊断为射血分数保留型心力衰竭（HFpEF）的受试者死亡或重大心脏不良事件（MACE）风险的方法。该方法可包括(a)在受试者的样本中确定至少一种因子中每种代谢物的水平，其中因子选自由因子1、因子3、因子4、因子5、因子10、因子12和因子14组成的组；以及(b)将样本中每种代谢物的水平与标准进行比较，其中受试者体内代谢物相对于标准的水平指示受试者的死亡或MACE风险。
• PREDICTING CORONARY ARTERY DISEASE AND RISK OF CARDIOVASCULAR EVENTS
  申请人：Duke University

  公开号：US20160195543A1

  公开（公告）日：2016-07-07

  Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease.
• COMPOSITIONS AND METHODS FOR METABOLIC PROFILING IN SUBJECTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
  申请人：Duke University

  公开号：US20180067137A1

  公开（公告）日：2018-03-08

  Disclosed herein are compositions and methods for targeted metabolomics profiling to provide absolute quantification of a broad array of metabolic intermediates of fatty acids, amino acids, and carbohydrate metabolism for HFpEF. In an aspect, the disclosure relates to a method for assessing risk of death or a major adverse cardiac event (MACE) in a subject diagnosed with heart failure with preserved ejection fraction (HFpEF). The method may include (a) determining in a sample from the subject the level of each metabolite in at least one factor, wherein the factor is selected from the group consisting of factor 1, factor 3, factor 4, factor 5, factor 10, factor 12, and factor 14; and (b) comparing the level of each metabolite in the sample to a standard, wherein the level of the metabolite in the subject relative to a standard is indicative of the risk of death or MACE in the subject.
• [EN] METHODS FOR IDENTIFYING SUPPLEMENTS THAT INCREASE GUT COLONIZATION BY AN ISOLATED BACTERIAL SPECIES, AND COMPOSITIONS DERIVED THEREFROM<br/>[FR] PROCÉDÉS POUR IDENTIFIER DES COMPLÉMENTS QUI AUGMENTENT LA COLONISATION INTESTINALE PAR UNE ESPÈCE BACTÉRIENNE ISOLÉE, ET COMPOSITIONS DÉRIVÉES
  申请人：UNIV WASHINGTON

  公开号：WO2015003001A1

  公开（公告）日：2015-01-08

  The invention encompasses methods for identifying supplements that support growth of a bacterial strain in the gut of a subject, and compositions derived therefrom.